Novartis Begins Patient Dosing and Enrollment in Phase 1/2 Trial of Gene Therapy 'DFT383' for Pediatric Nephropathic Cystinosis
Clinical Trial Initiation and Focus on Pediatric Patients
Novartis (NVS) has commenced patient enrollment and dosing in the Phase 1/2 trial (CYStem study, NCT06910813) of its gene therapy candidate, 'DFT383,' for Nephropathic Cystinosis. This study is designed to evaluate the safety and efficacy of the therapy in pediatric patients aged 2 to 5 years. With Novartis accelerating the development of this pipeline acquired from AVROBIO, it is expected to further solidify its position in the Cell and Gene Therapy (CGT) field. Given the rare nature of the disease, patient recruitment can be challenging, but the active enrollment is a positive sign.
Innovative Treatment Mechanism Based on Autologous Hematopoietic Stem Cells
DFT383 utilizes a mechanism that involves isolating the patient's autologous CD34+ hematopoietic stem and progenitor cells (HSPCs) and transducing them with a lentiviral vector to express normal CTNS genes, which are then re-infused into the patient. This technology aims to restore the normal production of cystinosin protein within the body, thereby fundamentally preventing the accumulation of cystine crystals in cells. While existing treatments only provide symptomatic relief, DFT383 represents a curative approach to address the underlying cause of the disease.
Overcoming Limitations of Existing Treatments and Promising Clinical Data
The current standard of care (SOC) for Nephropathic Cystinosis relies on cysteamine (brand name Procysbi) to inhibit cystine accumulation. However, Procysbi requires lifelong administration twice daily and can cause severe gastrointestinal side effects and a distinct body odor, leading to poor patient compliance. In contrast, preliminary results from a previous Phase 1/2 trial of DFT383 showed that all six adult patients who received the therapy experienced a sustained reduction in leukocyte cystine levels below baseline, with some patients able to discontinue oral cysteamine for up to 36 months.
Strategic Acquisition and Market Expansion Potential
Recognizing the potential of this therapy, Novartis acquired the entire program from AVROBIO in May 2023 for an upfront payment of $87.5 million. This all-cash deal, without milestones or royalties, demonstrates Novartis's commitment to maximizing its first-mover advantage, even if it means taking on some risk. The global market for Nephropathic Cystinosis treatment is estimated at $198.8 million in 2024 and is projected to grow to $465 million by 2033, making it a niche market with high growth potential. If a gene therapy that aims for a one-time cure is commercialized, it could secure a dominant market position.
Future Clinical Milestones and Long-Term Prospects
This trial began on June 2, 2025, and is on track to complete the primary phase by May 2031. Given that the gene is being introduced to young, growing pediatric patients, a long-term extension phase will be conducted to track safety and durability for up to 15 years. If Novartis can demonstrate complete safety in pediatric patients, it will not only provide innovative improvements in quality of life for patients who have suffered for a lifetime but also maximize the value of its rare disease portfolio.
DFT383, currently in Phase 1/2 clinical trials, is a first-in-class autologous hematopoietic stem cell (HSC) gene therapy that aims to overcome the limitations of existing standard-of-care treatments, such as oral cysteamine, which requires twice-daily lifelong administration and causes significant side effects. In an initial trial involving adult patients, all six patients successfully maintained reduced levels of cystine in their white blood cells for up to 36 months after treatment, without the need for further medication. Therefore, securing long-term safety data in pediatric patients will be a key indicator for subsequent approval. This program, acquired by Novartis from AVROBIO in 2023 for an upfront payment of $87.5 million, has the potential to secure a dominant market position in the Nephropathic Cystinosis market, which is expected to grow to approximately $465 million by 2033. This will serve as an important test case for demonstrating the value of one-time gene therapies in the area of pediatric rare diseases.
Source: ClinicalTrials.gov (api_ct)